The Oncologist: The effect of the combined use of PPIs on Cabozantinib in the treatment of metastatic renal cell carcinoma (mRCC)

Cabozantinib is an oral tyrosine kinase inhibitor approved for the treatment of metastatic renal cell carcinoma (mRCC)

Cabozantinib is an oral tyrosine kinase inhibitor approved for the treatment of metastatic renal cell carcinoma (mRCC)

Among 99 eligible patients, the median age was 61 years, and most patients were male (67 cases; 67.

Among 99 eligible patients, the median age was 61 years, and most patients were male (67 cases; 67.

Forty-three patients (43.

After the start of treatment with Cabozantinib, the median follow-up was 30.

PFS

In univariate analysis, longer PFS was associated with good and intermediate-risk IMDC scores at the beginning of cabozantinib treatment (HR, 0.

Cabozantinib-related adverse events included 61.

Adverse events

In an independent pharmacokinetic cohort, 21 people received PPI at the same time, and the residual concentrations between the two groups were similar

In an independent pharmacokinetic cohort, 21 people received PPI at the same time, and the residual concentrations between the two groups were similar

In summary, studies have shown that the combined use of PPIs does not significantly affect the efficacy and safety of Cabozantinib in the treatment of metastatic renal cell carcinoma (mRCC)
.
Studies have shown that the combined use of PPIs does not significantly affect the efficacy and safety of Cabozantinib in the treatment of metastatic renal cell carcinoma (mRCC)
.
Studies have shown that the combined use of PPIs does not significantly affect the efficacy and safety of Cabozantinib in the treatment of metastatic renal cell carcinoma (mRCC)
.

Original source:

Original source:

Rassy E, Cerbone L, Auclin E, Benchimoll-Zouari A, Flippot R, Alves Costa Silva C, Colomba E, Geraud A, Guida A, Mir O, Combarel D, Paci A, Escudier B, Albiges L.
The Effect of Concomitant Proton Pump Inhibitor and Cabozantinib on the Outcomes of Patients with Metastatic Renal Cell Carcinoma.
Oncologist.
2021 May;26(5):389-396.
doi: 10.
1002/onco.
13711.
Epub 2021 Feb 25.
PMID: 33554383; PMCID: PMC8100573 .

Rassy E, Cerbone L, Auclin E, Benchimoll-Zouari A, Flippot R, Alves Costa Silva C, Colomba E, Geraud A, Guida A, Mir O, Combarel D, Paci A, Escudier B, Albiges L.
The Effect of Concomitant Proton Pump Inhibitor and Cabozantinib on the Outcomes of Patients with Metastatic Renal Cell Carcinoma.
Oncologist.
2021 May;26(5):389-396.
doi: 10.
1002/onco.
13711.
Epub 2021 Feb 25.
PMID: 33554383; PMCID: PMC8100573 .


in this message